TCL1A and MECOM showed a strong interactive clinical hazard prediction in prospectively treated patients, suggesting a contribution of the described regulatory circuit to an aggressive cellular and clinical phenotype in CLL [29]. The gene discussed is TCL1A; the disease is B-cell chronic lymphocytic leukemia.